# Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma

> **NCT06718205** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 112 (estimated)

## Conditions studied

- Esophageal Cancer

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Sintilimab
- **DRUG:** Paclitaxel-albumin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT06718205
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-08
- **Primary completion:** 2025-09
- **Final completion:** 2025-09
- **Target enrollment:** 112 (ESTIMATED)
- **Last updated:** 2024-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06718205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06718205, "Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06718205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*